tirzepatide news november 2025 In adults with obesity but not diabetes, leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL ESC 2025: study supports use

The overarching issue is that compounded medications are not FDA-approved, which means their safety, efficacy, and quality are less predictable, says Dr

Jawline filler can be tailored for a more defined, sculpted, or softened look, depending on the patients preferences and facial structure

How this should shape your decision and monitoring For most people without a pancreatitis history, the evidence does not support avoiding a GLP-1 out of fear of the pancreas

Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study

Build habits and metabolic resilience while the medication provides a metabolic advantage

At our practice, your health and well-being are our top priorities